PRI-724
Undisclosed (β-catenin/CBP inhibitor)
Phase 1Active (Drug-drug interaction study by Ohara Pharmaceutical)
Key Facts
Indication
Undisclosed (β-catenin/CBP inhibitor)
Phase
Phase 1
Status
Active (Drug-drug interaction study by Ohara Pharmaceutical)
Company
About PRISM Biolabs
PRISM BioLab develops peptide-mimetic small molecules to drug challenging protein-protein interactions using its proprietary PepMetics® platform.
View full company profile